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Background  Sarcopenia has been shown to be an independent predictor of lower 
disease-free and overall survival in various kinds of diseases. The quality of skeletal muscle 
has recently attracted much attention as a new parameter of sarcopenia. 
Methods  We performed a retrospective analysis of 477 patients undergoing hepatectomy for 
HCC between April 2005 and August 2014. The quality of skeletal muscle was evaluated by 
intramuscular adipose tissue content (IMAC) using preoperative CT imaging. The impact of 
IMAC on outcomes after hepatectomy for HCC was analyzed.  
Results  Patients with high IMAC showed older age, higher body mass index, higher 
indocyanine green retention test at 15 min, and more operative blood loss. The overall and 
recurrence-free survival rates were significantly lower in patients with high IMAC than in 
patients with normal IMAC (P < 0.0001, P = 0.0012, respectively). Multivariate analysis 
showed that high IMAC was the significant risk factor for death (hazard ratio [HR] = 2.942; P 
< 0.0001) and for HCC recurrence (HR = 1.529; P = 0.0007) after hepatectomy.  
Conclusions  Preoperative quality of skeletal muscle was closely correlated with 
postoperative mortality and HCC recurrence. IMAC could be incorporated into new selection 





Sarcopenia is defined as a syndrome characterized by progressive and generalized loss of 
skeletal muscle mass and strength [1]. The prognostic significance of sarcopenia has been 
reported in various kinds of diseases including cancer [2–4]. Most previous studies have 
investigated only skeletal muscle mass to define sarcopenia because muscle strength and 
function are difficult to evaluate, though The European Working Group on Sarcopenia in 
Older People has recommended that the definition of sarcopenia should include not only low 
muscle mass, but also low muscle strength or function [1]. Recently, it has been reported that 
the increase in intramuscular adipose tissue (IMAT) with aging was associated with muscle 
weakness and poor function, one of the components of sarcopenia [5]. Kitajima et al [6]. 
showed that the quality of skeletal muscle could be evaluated by measuring intramuscular 
adipose tissue content (IMAC), and that IMAC was linked to the severity of non-alcoholic 
steatohepatitis (NASH). In our previous study, preoperative lower quality of skeletal muscle 
evaluated by IMAC was an independent and significant risk factor for poor survival in 
patients undergoing living donor liver transplantation [7].
 
Thus, the quality of skeletal muscle 
has recently attracted much attention as a new parameter of sarcopenia.
 
Hepatocellular carcinoma (HCC) is one of the most common human cancers, and its 
incidence is still increasing worldwide [8, 9]. HCC is a highly malignant tumor characterized 
by rapid progression, frequent tumor recurrence, and metastasis. To date, there has been no 
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successful systemic chemotherapy for patients with advanced HCC, and surgical treatment, 
including hepatectomy and liver transplantation, is the most effective modality for the 
treatment for HCC [9]. While advances in preoperative diagnosis, surgical technique, and 
perioperative management have improved overall and recurrence-free survival after partial 
hepatectomy for HCC, even in patients with curative resection, the postoperative recurrence 
rate remains high, with a five-year recurrence rate of up to 70% [10]. 
Recent study has shown that sarcopenia defined as lower skeletal muscle mass was an 
independent prognostic factor for mortality after hepatectomy for HCC [11, 12]. However, 
measuring only the area of skeletal muscle using CT imaging may not be sufficient to 
evaluate lean muscle mass because we could not distinguish muscle from adipose tissue with 
that method, which might mislead us to evaluate low lean muscle mass with much adipose 
tissue as normal skeletal muscle mass.
 
In the present study, we evaluated the quality of skeletal muscle by measuring IMAC as a 
new parameter of sarcopenia, and investigated the impact of sarcopenia on outcomes in 
patients undergoing hepatectomy for HCC. 
 
Patients and methods 
Patients 
There were 547 patients who underwent hepatectomy for HCC at Kyoto University Hospital 
6 
 
between April 2005 and August 2014. Seventy patients who did not have preoperative plain 
computed tomography (CT) imaging at the umbilical level were excluded from this study. 
Therefore, a total of 477 patients (389 men, 88 women) were enrolled in the present study. 
The study was approved by the Ethics Committee of Kyoto University and conducted in 
accordance with the Declaration of Helsinki of 1996. 
Hepatic resection was usually performed using the Cavitron Ultrasonic Surgical Aspirator 
(CUSA) and a bipolar cautery device equipped with a channel for water dripping, with an 
intermittent Pringle maneuver, or selective vascular clamping if necessary. A pathological 
examination was performed to evaluate tumor size, tumor number, vascular invasion, tumor 
differentiation, and background liver in accordance with the rules of the Liver cancer Study 
Group of Japan. 
All patients were followed up every three months after operation with evaluation of tumor 
markers and CT or magnetic resonance imaging. 
 
Imaging analysis 
All CT imaging was obtained with a multidetector computed tomography scanner (Aquilion 
64, Toshiba Medical Systems, Tochigi, Japan). The technical parameters used for CT were as 
follows: 120 kV (tube voltage), 0.5 mm × 64 row (detector configuration), tube current 
modulation, 0.5 sec/rotation (gantry rotation), and 7 mm reconstruction thickness. 
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The quality of skeletal muscle was evaluated by IMAC. IMAC was calculated as previously 
described:  
IMAC = region of interest (ROI) of the multifidus muscle (Hounsfield units)/ROI of 
subcutaneous fat (Hounsfield units) [6, 7].
 
Subfascial muscular tissue in the multifidus muscle on the preoperative plain CT 
cross-sectional image at the umbilical level was precisely traced, and CT values (in 
Hounsfield units) were measured using the AquariusNET server (TeraRecon, Inc., San Mateo, 
CA, USA) (Fig. 1a). CT values were measured for ROIs of four circles on subcutaneous fat 
away from major vessels (Fig. 1b). The mean values of those four ROIs were used as the ROI 
of subcutaneous fat. In general, IMAC was shown with a negative value. Skeletal muscle with 
more IMAT shows higher IMAC, so higher IMAC means lower quality of skeletal muscle. 
The quantity of skeletal muscle was evaluated by psoas muscle mass index (PMI). The 
cross-sectional areas of the bilateral psoas muscles were measured by manual tracing using 
preoperative CT images at the same level (Fig. 1c). The psoas muscle mass index (PMI) was 





Receiver operating characteristic (ROC) curves were calculated in order to select the optimal 
cut-off values of IMAC and PMI for men and women separately. The cut-off values were 
selected on the basis of best accuracy in relation to an outcome (death). The cut-off values of 
IMAC in males and females were -0.324 (area under the curve [AUC] = 0.687) and -0.138 
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(AUC = 0.651), respectively. The cut-off values of PMI were 6.089 (AUC = 0.548) and 4.020 







The overall and recurrence-free survival rates after hepatectomy were investigated in patients 
classified according to IMAC or PMI. The prognostic factors were analyzed on the basis of 
the following variables: patient age, sex, etiology of HCC, the presence of treatment history 
for HCC before hepatectomy, platelet count, indocyanine green retention test at 15 min (ICG 
R15), Child-Pugh classification, serum α-fetoprotein (AFP) level, des-γ-carboxyprothrombin 
(DCP) level, liver histology, tumor size, number of tumors, microvascular invasion (MVI), 
tumor differentiation, pathological stage according to the Liver Cancer Study Group of Japan, 
surgical procedure, duration of surgery, estimated operative blood loss, body mass index 
(BMI), preoperative IMAC, and preoperative PMI.  
 
Statistical analysis 
Continuous variables were nonparametrically analyzed using the Mann-Whitney U test. 
Categorical variables were compared using the χ² test or Fisher’s exact test where appropriate. 
Correlation between continuous variables was assessed using Pearson correlation coefficients 
and linear regression. Cumulative overall and recurrence-free survival rates were calculated 
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using Kaplan-Meier methods, and differences between curves were evaluated using the 
log-rank test. Any variable identified as significant (P < 0.05) or with P < 0.10 in univariate 
analysis was considered a candidate for a multivariate Cox regression analysis. A P value < 
0.05 was considered significant. All statistical data were generated using JMP 11 (SAS 




The baseline characteristics and laboratory data of the 477 patients are shown in Table 1. The 
median patient age was 68 years (range, 31–89 years). The Child-Pugh classifications were A 
and B for 437 (92%) and 40 patients (8%), respectively. Two hundreds and eighty-nine 
patients (61%) underwent primary hepatectomy as the initial treatment for HCC, while 189 
patients (39%) had treatment history before hepatectomy such as TACE or RFA. The median 
tumor size was 3.5 cm (range, 0.2–25 cm). Pathological stages according to the Liver Cancer 
Study Group of Japan were I, II , III, and IV for 82 (17%), 181 (38%), 142 (30%), and 72 
patients (15%), respectively. Microvascular invasion was identified in 152 patients (32%).  
A significant positive relationship was observed between IMAC and patient age in both 
males (r = 0.368, P < 0.0001) and females (r = 0.535, P < 0.0001); therefore, the mean age in 
patients with high IMAC was significantly higher than in patients with normal IMAC (P < 
10 
 
0.0001). Similarly, BMI in patients with high IMAC was significantly higher than in patients 
with normal BMI (P = 0.0002). The patients with normal IMAC showed more hepatitis B 
virus (HBV) or hepatitis C virus (HCV)-related HCC than those with high IMAC (P = 
0.0350). Among preoperative laboratory data, only ICG R15 was significantly higher in 
patients with high IMAC than in patients with normal IMAC (P = 0.0485). Tumor-associated 
factors were not significantly different between the two groups. Among operative factors, 
estimated blood loss in patients with high IMAC was significantly higher than in patients with 
normal IMAC (P = 0.0225). 
 
Overall and recurrence-free survival rates after hepatectomy 
The overall survival rate after hepatectomy for HCC was significantly lower in patients with 
high IMAC than in patients with normal IMAC (P < 0.0001; Fig. 2a). In patients classified 
according to PMI, the overall survival rate was not significantly different between the two 
groups (P = 0.3178; Fig. 2b). The recurrence-free survival rate was significantly lower in 
patients with high IMAC than in patients with normal IMAC (P = 0.0012; Fig. 2c). The 
recurrence-free survival rate in patients with low PMI was not significantly different from in 
patients with normal PMI (P = 0.7468; Fig. 2d). 
 
Risk factors for poor outcomes in patients undergoing hepatectomy 
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The results of univariate and multivariate analysis of the overall survival in patients 
undergoing hepatectomy for HCC are shown in Table 2. A multivariate Cox regression 
analysis identified high serum AFP level (≥20 ng/dl), advanced TNM stage, preoperative high 
IMAC as independent risk factors for death after hepatectomy (Table 2).  
Table 3 shows the results of univariate and multivariate analysis of the recurrence-free 
survival. Multivariate analysis showed that liver histology (liver fibrosis or liver cirrhosis), 
larger tumor size (≥5.0 cm), MVI, advanced TNM stage, and preoperative high IMAC were 
independent risk factors for HCC recurrence (Table 3). 
 
Discussion 
This retrospective study was the largest and first study to show that preoperative IMAC was 
the most significant prognostic factor for overall and recurrence-free survival in patients 
following hepatectomy for HCC. Recently, sarcopenia has attracted much attention as a 
prognostic factor for poor outcome in various kinds of diseases [2–4, 11, 12]. Although most 
recent studies have investigated only skeletal muscle mass to evaluate sarcopenia using CT 
imaging, measuring only the area of skeletal muscle using CT imaging may not be sufficient 
to evaluate lean muscle mass because we could not distinguish muscle from adipose tissue 
with that method. In other words, PMI does not always reflect actual muscle mass because the 
areas of psoas muscles measured in the present study include both muscle and IMAT. In some 
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patients with a large amount of IMAT, their PMI could be calculated as normal even if their 
actual amount of muscle mass was low. Therefore, only measuring PMI could not detect such 
patients as having sarcopenia. On the other hand, high IMAC reflects not only more IMAT but 
also less muscle mass because IMAC is calculated as the ratio of CT values between skeletal 
muscle and subcutaneous fat tissue. In addition, a recent report from the Health, Aging and 
Body Composition (Health ABC) Study Cohort showed that the loss of strength was 
surprisingly much greater than the loss of muscle mass, which indicated that decline in 
muscle quality contributed to loss of strength [13]. It has been also shown that fat 
accumulation within skeletal muscle is associated with muscle weakness, poor function, and 
increased risk of incidental mobility limitations because it alters muscle fiber orientation and 
the force-producing capabilities of the whole muscle [14–16]. On the basis of these findings, 
we considered that IMAC could substitute for evaluation of muscle strength or function and 
could be the most appropriate parameter to evaluate preoperative sarcopenia instead of 
measuring only the cross-sectional areas of skeletal muscle. 
The mechanisms by which sarcopenia produces an increased risk of mortality and morbidity 
are not fully understood. In the present study, patient age, BMI, preoperative ICG R15 and 
operative blood loss were significantly different between high IMAC group and normal 
IMAC group. Operative blood loss has been reported as independent prognostic factors for 
death or tumor recurrence after hepatectomy for HCC [17]. Among these parameters, only 
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operative blood loss was shown to be a significant risk factor for death or HCC recurrence 
after hepatectomy as a result of univariate analysis, while it was not an independent risk factor. 
Recent evidence has shown that skeletal muscle loss with increasing adipose tissue leads to 
synthesize and secrete various kinds of pro-inflammatory adipokines such as leptin, TNF-α, 
interleukin (IL)-1 and IL-6 [18]. Lutz et al. [19] showed that increase of such adipokines and 
decrease in adiponectin or IL-15 levels in aged or sarcopenic population had effects on the 
immune senescence, especially natural killer lymphocytes in innate immunity. Indeed, in the 
present study, we found more infectious postoperative complications in patients with high 
IMAC than in patients with normal IMAC (22.0% vs 9.7%; P = 0.0002). This result is in line 
with previous study that showed the presence of sarcopenia increases the risk of sepsis-related 
death in cirrhotic patients, which might be due to impaired immunity [20]. Recently, with 
increased interest towards subsets of obesity-associated tumors, the role of adipose and 
muscle tissue interplay in carcinogenesis and cancer progression has attracted much attention 
[21, 22]. It has been shown that among various kinds of adipokines, anti-inflammatory 
cytokines such as adiponectin presents anti-tumorigenic effects via various mechanisms [21]. 
On the other hands, pro-inflammatory adipokines such as leptin has been shown to promote 
growth and proliferation of tumor cells via activation various growth and survival signaling 
pathways [21]. In HCC, Sharma D et al. [23] reported that adiponectin has the molecular 
potential to inhibit the oncogenic actions of leptin by blocking Stat 3 and Akt phosphorylation. 
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On the basis of these findings, we speculate that the increase in adiposity in sarcopenic 
patients could lead to imbalance between adipokines and myokines, which results in cancer 
growth and recurrence.  
To improve sarcopenic status, beneficial effects can be obtained through exercise and amino 
acid supplementation using leucine-enriched mixture, by their regulation of mTOR signaling 
[24]. Today, BCAA nutrients, synbiotics and immune-modulating diet enriched with 
hydrolyzed whey peptide are used for all recipients as pre- and postoperative enteral nutrition 
in our institution. In our previous study, we found that perioperative nutritional therapy 
significantly improved posttransplant mortality in patients with low skeletal muscle mass 
measured by bioelectrical impedance analysis [25]. On the basis of these results, we are 
planning to prospectively evaluate the effect of preoperative nutritional therapy for 
improvement of IMAC, and investigate the impact of changes in IMAC on postoperative 
outcomes after hepatectomy for HCC. 
The present study has several limitations. First, there was a possibility of selection bias for 
patient inclusion in the study group because as many cases were excluded from this study. We 
excluded 70 patients (12.8%) for the sole reason of their having undergone no CT imaging at 
the umbilical level. This exclusion criterion was not related to the patients’ general condition 
and severity of disease. Indeed, the mean values of preoperative blood examinations, the 
distribution of the Child-Pugh classification scores, etiology of HCC, operative factors, and 
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tumor factors in this excluded population were almost similar to those of the study group. 
Therefore, there was actually little selection bias for patient inclusion in the present study. 
Second, we have to consider whether our cut-off values for IMAC and PMI were adequate to 
define sarcopenia. To date, several reports have each provided a definition of sarcopenia, but 
there is no criterion to define sarcopenia objectively [26, 27]. In the present study, we used 
ROC curves to determine the cut-off values of IMAC and PMI. The use of ROC curves is a 
more accurate and objective method than the use of SD for the design of cut-off values. We 
are now investigating IMAC and PMI considering age, sex, and BMI in healthy donors of 
liver transplantation; this investigation may determine more adequate cut-off values of IMAC 
and PMI to define sarcopenia.  
In conclusion, the present study showed that the low quality of skeletal muscle evaluated by 
measuring IMAC was closely correlated with poor outcomes in patients undergoing 
hepatectomy for HCC. Preoperative IMAC could be incorporated into new selection criteria 
for hepatectomy for HCC. 
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Figure legends 
Fig. 1 Cross-sectional computed tomographic images of (a) subfascial muscular tissue in the 
multifidus muscle, (b) subcutaneous fat (four small circles) and (c) bilateral psoas muscles at 
the umbilical level. 
Fig. 2 (a) Overall survival rates after hepatectomy in patients classified according to IMAC. 
The overall survival rate was significantly lower in patients with high IMAC than in patients 
with normal IMAC (P < 0.0001). (b) Overall survival rates after hepatectomy in patients 
classified according to PMI. The overall survival rate was not significantly different between 
the two groups (P = 0.3178). (c) Recurrence-free survival rates after hepatectomy in patients 
classified according to IMAC. The recurrence-free survival rate was significantly lower in 
patients with high IMAC than in patients with normal IMAC (P = 0.0012). (d) 
Recurrence-free survival rates after hepatectomy in patients classified according to PMI. The 
recurrence-free survival rate in patients with low PMI was not significantly different from in 





Table 1  Characteristics of patients classified according to IMAC 
Characteristic Total 
(n = 477) 
High IMAC 
(n = 209) 
Normal IMAC 
(n = 268) 
P
Age (years) 
 Mean (SD) 67 (10) 71 (7) 64 (10) <0.0001













Mean (SD) 23.1 (3.4) 23.9 (3.6) 22.6 (3.1) 0.0002 
Preoperative IMAC 
Males 
  Mean (SD) 
Females 



















Etiology, n (%) 
























Mean (SD) 15.4 (7.0) 15.3(7.2) 15.4 (6.9) 0.9642
ICG R15 (%) 
 Mean (SD) 17.0 (10.3) 18.0 (10.5) 16.3 (10.1) 0.0485 






























Liver histology, n (%) 
Normal liver + chronic hepatitis 








Tumor size (cm) 
 Mean (SD) 4.8 (3.8) 5.0 (3.9) 4.7 (3.8) 0.3326 










MVI, n (%) 
Table 2  Prognostic factors for overall survival on univariate and multivariate analysis 
 Univariate analysis  Multivariate analysis 
 MST (months) P  Hazard ratio 95% CI P 
Age (years) 
 ≥65 (n = 169) 






    
Gender 
 Male (n = 389) 






    
Etiology of HCC 
 HBV or/and HCV (n =319) 






    
The presence of previous treatment 
for HCC 
 Yes (n = 188) 














 <10 (n = 101)  













ICG R15 (%) 
 ≥15 (n = 245) 






    
Child-Pugh classification 
 A (n = 437) 






    
AFP (ng/dl) 
 ≥20 (n = 229) 














 ≥40 (n = 338) 






    
Liver histology 
 Normal liver or chronic hepatitis 
  (n = 239) 
 Liver fibrosis or liver cirrhosis 







    
Tumor size (cm) 
 ≥5.0 (n =170) 













Number of tumors 
 Multiple (n = 153) 














 Positive (n = 152) 














 Well or moderate (n = 349) 
















 I or II (n = 263) 
















 ≥Lobectomy (n = 167) 













Operative time (min) 
 ≥360 (n = 250) 













Operative blood loss (ml) 
 ≥500 (n =310) 

















 ≥25 (n = 109) 






    
Preoperative IMAC 
 High (n = 209) 















 Low (n = 134) 






    
AFP, α-fetoprotein; BMI body mass index, CI confidence interval, DCP des-γ-carboxyprothrombin, HBV hepatitis B virus, 
HCC hepatocellular carcinoma, HCV hepatitis C virus, ICG R15 indocyanine green retention test at 15 min, IMAC 
intramuscular adipose tissue content, MST median survival time, MVI microvascular invasion, PMI psoas muscle mass index, 






































































Operative time (min) 









Operative blood loss (ml) 









AFP α-fetoprotein, BMI body mass index, DCP des-γ-carboxyprothrombin, HBV hepatitis B virus, HCC hepatocellular 
carcinoma, HCV hepatitis C virus, ICG R15 indocyanine green retention test at 15 min, IMAC intramuscular adipose tissue 
content, MVI microvascular invasion, PMI psoas muscle mass index, SD standard deviation, TNM Tumour Node Metastasis 
(stage defined by the Liver Cancer Study Group of Japan).  
Percentages might not add up to 100% because of rounding. 
 
Table 3  Prognostic factors for recurrence-free survival on univariate and multivariate analysis 
 Univariate analysis  Multivariate analysis 
 MST (months) P  Hazard ratio 95% CI P 
Age (years) 
 ≥65 (n = 169) 






    
Gender 
 Male (n = 389) 






    
Etiology of HCC 
 HBV or/and HCV (n =319) 






    
The presence of previous treatment 
for HCC 
 Yes (n = 188) 























 <10 (n = 101)  













ICG R15 (%) 
 ≥15 (n = 245) 






    
Child-Pugh classification 
 A (n = 437) 






    
AFP (ng/dl) 
 ≥20 (n = 229) 














 ≥40 (n = 338) 














 Normal liver or chronic hepatitis 
  (n = 239) 
 Liver fibrosis or liver cirrhosis 

















Tumor size (cm) 
 ≥5.0 (n =170) 













Number of tumors 
 Multiple (n = 153) 














 Positive (n = 152) 














 Well or moderate (n = 349) 
















 I or II (n = 263) 















 ≥Lobectomy (n = 167) 













Operative time (min) 
 ≥360 (n = 250) 






    
Operative blood loss (ml) 
 ≥500 (n =310) 

















 ≥25 (n = 109) 






    
Preoperative IMAC 
 High (n = 209) 















 Low (n = 134) 






    
AFP, α-fetoprotein; BMI body mass index, CI confidence interval, DCP des-γ-carboxyprothrombin, HBV hepatitis B virus, 
HCC hepatocellular carcinoma, HCV hepatitis C virus, ICG R15 indocyanine green retention test at 15 min, IMAC 
intramuscular adipose tissue content, MST median survival time, MVI microvascular invasion, PMI psoas muscle mass index, 
TNM Tumour Node Metastasis (stage defined by the Liver Cancer Study Group of Japan). 
 
